Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Rubius Therapeutics, Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$81.3 Billion
Q2 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.79 - $5.98 $19,066 - $144,327	-24,135 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$4.25 - $10.4 $12,027 - $29,432	2,830 Added 13.28%	24,135 $133,000
Q4 2021 Feb 07, 2022	BUY	$9.68 - $17.74 $91,553 - $167,784	9,458 Added 79.83%	21,305 $222,000
Q3 2021 Nov 04, 2021	BUY	$17.6 - $25.91 $5,984 - $8,809	340 Added 2.95%	11,847 $212,000
Q2 2021 Aug 06, 2021	BUY	$22.26 - $28.43 $256,145 - $327,144	11,507 New	11,507 $281,000

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account